|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
���������ۺ��� |
|
ҩ���Ʒ� |
|
������������ |
| ��������������� | |
|
���Ŀ� |
|
���̸� |
| PubMed | |
|
Article by |
|
Article by |
��������ijЩ���ƽ�չ
���Ŀ�, ���̸�
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
��������һ�����ԡ���֢�ԡ���ϵͳ���ۡ��������ļ���,������Ϊ��ǻ������ֳ������,����Ĥ�ס��ؽ��ס�Ѫ���ס�θ������������ϵͳ֢״�ȡ������ϳ��õ�ҩ�����:��ˮ�ɼ�������ʡ�ɳ���Ȱ��������ᵪ�桢�����ء�������-������Ƥ�ʼ��صȡ���������Ϊ��������������ҩ�����ư�������ȫ��Ч��
[2] Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther, 2003,5:139-146.
[3] Evereklioglu C. Managing the symptoms of Behcet's disease. Expert Opin Pharmacother, 2004, 5:317-328.
[4] Yazici H. Behcet's syndrome:where do we stand? Am JMed, 2002,112:75-76.
[5] No authors listed. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet, 1990, 335:1078-1080.
[6] Sakane T, Takeno M. Current therapy in Behcet's disease. Skin Therapy Lett, 2000,5:3-5.
[7] Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Derm atology, 1996,192:125-128.
[8] Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med, 1990, 322:281-285.
[9] Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome:effects on long-term prognosis. Arthritis Rheum, 1997,40:769-774.
[10] Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized,double-blind, placebo-controlled trial. Ann Intern Med, 1998, 128:443-450.
[11] O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med, 1984, 76:75-84.
[12] Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet, 1989, 1:1093-1096.
[13] Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol, 1994, 118:39-45.
[14] Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behcet's syndrome. J Rheumatol, 1994,21:1098-1100.
[15] Wechsler B, Du-Boutin LT. Interferons and Behcet's disease. Rev Med Interne, 2002,23:S495-S499.
[16] Kotter I, Gunaydin I, Zierhut M,et al. The use of interferon alpha in Behcet disease:review of the literature. Semin Arthritis Rheum,2004,33:320-335.
[17] Kattsambis AD. European Handbook of Dermatological Treatment.Berlin:Springer, 1999.21-30.
[18] Mahe E, Descamps V. Anti-TNF alpha in dermatology. Ann Dermatol Venereol, 2002, 129:1374-1379.
[19] Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis, 2001, 60:637.
[20] Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford),2001, 40:473-474.
[21] Hassard PV, Binder SW, Nelson V,et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease:a case report. Gastroenterology, 2001, 120:995-999.
[22] Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut, 2001,49:725-728.
[23] Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet,2001, 358:1644.
[24] Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet,2001, 358:295-296.
[25] Simsek H, Dundar S,Telatar H. Treatment of Behcet disease with indomethacin. Int J Dermatol, 1991,30:54-57.